This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Official registry: https://clinicaltrials.gov/study/NCT05858619 · University of California, San Francisco · enrollment listed as 15
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Dupilumab. The registry lists allocation as na. This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
They plan to enroll about 15 people at San Francisco. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Molecular Signatures of Cutaneous Dupilumab Response
Interventions: Dupilumab
Primary outcome (registry wording): Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks
Jeffrey Cheng, MD, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
NCT00177268 · Official ClinicalTrials.gov record · University of Pittsburgh
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.
NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)
Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.
NCT01631617 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary